arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

TREACE MEDICAL CONCEPTS, INC.

TMCI
$4.17 ▼ -0.32 (-7.03%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
28 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
21
Health
Poor
Bearish
auto_awesome

Analytical Summary

TREACE MEDICAL CONCEPTS, INC. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $271.3M
Dividend Yield —
Revenue Growth -4.2% ↗
Op. Margin -33.0% ↗
ROIC -9.5% ↗
FCF / Share $-0.11 ↘
Trailing P/E —
Price / Book 4.0x
FCF Yield —
Debt / Equity 0.87
info Valuation on last close. End-of-day price, Nov 5, 2026.

28-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$45.38M
↓ -4.2% —
Net Income Profit after all expenses
$-17.96M
↓ -12.8% —
Operating Margin Operating profit as % of sales
-33.0%
↑ +9.4% 9th
FCF / Share Free cash flow per share
$-0.11
↓ -264.0% —
Long-Term Debt Long-term obligations
$56.04M
— +0.4% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↓
9
Returns ↓
13
Financial Health →
36
Cash Quality ↓
40

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 8 years · 28 quarters